A study to evaluate the efficacy and safety of Nafamostat Mesilate in treatment of Coronavirus infection : An Open Label, Randomized, Multicenter, Controlled Clinical Study to Evaluate the Efficacy and Safety of Nafamostat Mesilate in the Treatment of Moderate COVID-19 Disease
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
WHO International Clinical Trials Registry Platform - (2021) vom: 24. Nov. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
610 |
|---|
| Anmerkungen: |
WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 29-06-2020, Last updated: 2022-11-24 |
|---|
| ICTRP ID: |
CTRI/2020/06/026220 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
CTG004296532 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG004296532 | ||
| 003 | DE-627 | ||
| 005 | 20230425165333.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210507s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG004296532 | ||
| 035 | |a (UBBS_Klinische_Studien_WHO)CTRI/2020/06/026220 | ||
| 035 | |a (UBBS_Klinische_Studien_WHO)ICR/20/004 | ||
| 035 | |a (UBBS_Klinische_Studien_WHO)Version No. 1.0 | ||
| 035 | |a (UBBS_Klinische_Studien_WHO)Dated 23/APR/2020 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a A study to evaluate the efficacy and safety of Nafamostat Mesilate in treatment of Coronavirus infection |b An Open Label, Randomized, Multicenter, Controlled Clinical Study to Evaluate the Efficacy and Safety of Nafamostat Mesilate in the Treatment of Moderate COVID-19 Disease |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 29-06-2020, Last updated: 2022-11-24 | ||
| 650 | 4 | |a Medical Condition: Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Phase: Phase 2 | |
| 650 | 4 | |a Recruitment Status: Completed | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t WHO International Clinical Trials Registry Platform |g (2021) vom: 24. Nov. |
| 773 | 1 | 8 | |g year:2021 |g day:24 |g month:11 |
| 856 | 4 | 0 | |u http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44350 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 24 |c 11 | ||